Innovation Pharmaceuticals Inc (IPIX)

[LilyGDog]

There is some very strong language in this release.

Go Leo & IPIX!

Journal Article on Defensins Highlights Brilacidin’s Potential as a Broad Spectrum Antiviral

Innovation wanted to bring to the attention of shareholders a recent review article that supports defensins as a source of potential therapeutics against viral infections.

Solanki SS, Singh P, Kashyap P, Sansi MS, Ali SA.
“Promising role of defensins peptides as therapeutics to combat against viral infection.”
Microb Pathog. 2021 Apr 29:104930. doi: 10.1016/j.micpath.2021.104930. Epub ahead of print. PMID: 33933603.
https://www.sciencedirect.com/science/article/pii/S0882401021002023

As the article conveys, newer mechanistic insights are elucidating the intrinsic and multi-faceted abilities of defensins—a type of small antimicrobial peptide—to confer protection against many types of viruses.

Brilacidin, a defensin-mimetic designed and optimized to capture the biological properties of naturally occurring defensins, was highlighted in the article:

Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.

With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.

Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.